Navigation Links
Torbjorn Bjerke Appointed as new CEO for Karolinska Development
Date:8/23/2010

tent.prnewswire.com/designimages/widetable-release.JPG" style="border:0px" alt="Click to view news release full screen">  

Torbjorn Bjerke Appointed as new CEO for Karolinska Development

 

STOCKHOLM, August 23, 2010 /PRNewswire/ -- Torbjorn Bjerke has been appointed as new CEO for Karolinska Development. He is currently CEO for Orexo, a position he has held since 2007. Torbjorn Bjerke succeeds Conny Bogentoft who will assume the position as Chief Scientific Officer for Karolinska Development.

Starting its operation in 2003, Karolinska Development has rapidly become one of the leading companies within early pharmaceutical development in Europe. Investments by Karolinska Development have focused on developing its portfolio companies to proof of concept. Karolinska Development has now entered a next phase where the company will seek external partners for some of its portfolio companies while preparing for an initial public offering.

"With his solid background as a commercial leader, Torbjorn Bjerke has the right profile for the role as CEO for Karolinska Development. He has vast experience from leading and developing early research-based companies as well as a listed pharmaceutical company. Torbjorn's experience in business development and his demonstrated ability in negotiating and implementing collaborations with international partners will be of great value to us, our shareholders and our portfolio companies," says Hans Wigzell, Chairman of Karolinska Development.

Torbjorn Bjerke has held the position as CEO for Orexo since 2007. He will assume the position as CEO for Karolinska Development when his successor has been appointed. Conny Bogentoft, who has held the position as CEO for Karolinska Development since its inception in 2003, will become Chief Scientific Officer with overall responsibility for the future development of Karolinska Develop
'/>"/>

SOURCE Karolinska Development AB PUBL
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shawn Cross Appointed CEO of Burrill Merchant Banking Group
2. New President and CEO appointed at Ocean Nutrition Canada Limited
3. Professor Sander van Deventer Appointed to Supervisory Board of AMT
4. New Board Director Appointed
5. China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor
6. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
7. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
8. Lori Kahler Appointed President of The RC Insight Group
9. Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
10. FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout
11. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  AtheroNova Inc. (OTCBB: AHRO), a ... of compounds to safely regress atherosclerotic plaque and ... its partner, CardioNova, has accomplished first dosing of ... AtheroNova,s lead compound, AHRO-001.  This Phase 1b trial ... 1 safety trial completed in February 2014, in ...
(Date:7/30/2014)... Hartford, CT (PRWEB) July 30, 2014 ... economic development organization based in East Hartford, Conn., was ... on Phase II of a project that will determine ... facility in rural north-central Connecticut. USDA Rural Development provided ... (RBEG) program for the second phase of the feasibility ...
(Date:7/30/2014)... 2014 Immunology Summit-2014 ... Principle Investigators, scientists in the field, which includes ... at Case Western Reserve University School of Medicine, ... on “The effects of recombinant human IL-6 ... metalloproteinase-9”. Arya Biragyn, a Senior investigator at National ...
(Date:7/29/2014)... 2014 “PharmaSphere: Emerging Biotech Investment ... Capital Funding” report provides in-depth analysis of the ... and venture capital segments of the financial industry, ... have significant impact on the future of emerging ... the report identifies regions of the world that ...
Breaking Biology Technology:AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4
... KALAMAZOO, Mich., Oct. 28 Stryker Corporation (NYSE: SYK ... District of Massachusetts has returned an indictment charging Stryker Biotech ... with wire fraud, conspiracy to defraud the U.S. Food and ... statements to the FDA. The Company disclosed in March of ...
... INCLINE VILLAGE, Nev., Oct. 28 PDL BioPharma, Inc. ... has priced a $300 million securitization transaction intended to ... , Upon closing of the transaction, which is expected ... sell to QHP Royalty Sub LLC ("QHP"), a newly-formed ...
... , GAITHERSBURG, Md., Oct. 28 GenVec, Inc. (Nasdaq: ... the third quarter ended September 30, 2009 on Thursday, November ... call at 10:00 a.m. EST on Friday, November 6, 2009 ... http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) , To listen to ...
Cached Biology Technology:Stryker Statement in Response to the Indictment of Its Biotech Division 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3GenVec Announces Third Quarter 2009 Results Conference Call 2
(Date:7/30/2014)... pledge of $1 million from the Cornelia Cogswell Rossi ... Biometry Center. , The newly established Connie ... to develop a greater breadth and depth of knowledge ... the pace of research to improve human health. , ... for the Laboratory and its external partners, supporting research ...
(Date:7/30/2014)... July 30, 2014 ResearchMoz ... Government Biometric Systems Market 2014-2024   Business Strategies, Industry ... Biometric Systems Market 2014-2024" offers the reader detailed ... the next ten years, alongside potential market opportunities ... forecasts. To view the table of ...
(Date:7/30/2014)... across-the-board increase in Impact Factors for its molecular ... Reports (Thomson Reuters, 2014) show that Clinical ... in Biochemistry , Biochemical Society Transactions ... in their Impact Factors. The journals are owned ... Press Limited. , 2014 Impact Factors (2013 Impact ...
Breaking Biology News(10 mins):Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10Across-the-board Impact Factor increases for Portland Press Limited 2
... / b3c newswire / - Kinaxo Biotechnologies GmbH has ... identify the protein kinase mTOR as a new ... a non-steroidal, anti-inflammatory Cox-2 inhibitor approved for the ... In addition, celecoxib’s anti-proliferative effect has earned it ...
... of memories for a lifetime. But when our eyes ... also creates temporary memories that help us process complex ... For decades, scientists have held that such short-term memories ... the course of several seconds. Now researchers at ...
... of healthy people can cause serious infections in premature ... university Karolinska Institutet have now found an explanation for ... to the skin and quickly develop dynamic ecosystems: the ... establishes itself on the child,s skin and mucous ...
Cached Biology News:KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex 2Some short-term memories die suddenly, no fading 2Tufted bacteria cause infection in premature babies 2
Recombinant Feline IL-2, CF...
Recombinant Equine IL-4, CF...
Recombinant Rat Leptin, CF...
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: